Table 2.
PrePF versus No Fibrosis, Plasma Protein Analysis
| Protein | Protein Name | Coefficient | 95% CI | P Value | FDR |
|---|---|---|---|---|---|
| GSN | Gelsolin | −0.14 | −0.22 to −0.07 | 0.0002 | 0.003 |
| S100A9 | Protein S100-A9 | −0.73 | −1.11 to −0.35 | 0.0002 | 0.003 |
| CRKL | Crk-like protein | −0.23 | −0.37 to −0.10 | 0.0006 | 0.005 |
| LBP | LPS-binding protein | 0.21 | 0.08 to 0.35 | 0.0013 | 0.006 |
| C1QC | Complement C1q subcomponent subunit C | −0.22 | −0.35 to −0.09 | 0.0011 | 0.006 |
| S100A8 | Protein S100-A8 | −0.67 | −1.13 to −0.25 | 0.0021 | 0.009 |
| BASP1 | Brain acid soluble protein 1 | −0.32 | −0.55 to −0.10 | 0.0042 | 0.015 |
| SPARC | SPARC | 0.35 | 0.09 to 0.61 | 0.0075 | 0.024 |
| APOA4 | Apolipoprotein A-IV | −0.18 | −0.32 to −0.05 | 0.0093 | 0.026 |
| C9 | Complement component C9 | 0.18 | 0.04 to 0.31 | 0.011 | 0.027 |
| ALB | Serum albumin | −0.08 | −0.15 to −0.02 | 0.014 | 0.031 |
| CRISP3 | Cysteine-rich secretory protein 3 | −0.32 | −0.61 to −0.04 | 0.023 | 0.049 |
| APOA1 | Apolipoprotein A-I | −0.12 | −0.24 to −0.01 | 0.026 | 0.050 |
| PRSS3 | Trypsin-3 | 0.27 | 0.03 to 0.51 | 0.029 | 0.051 |
| YTHDC2 | Probable ATP-dependent RNA helicase YTHDC2 | −0.12 | −0.24 to −0.01 | 0.034 | 0.058 |
| PGLYRP2 | N-acetylmuramoyl-l-alanine amidase | −0.13 | −0.25 to −0.01 | 0.038 | 0.057 |
| CLEC3B | Tetranectin | −0.14 | −0.27 to −0.01 | 0.044 | 0.062 |
| APOA2 | Apolipoprotein A-II | −0.12 | −0.23 to −0.002 | 0.047 | 0.062 |
| A2M | Alpha-2-macroglobulin | 0.16 | 0.0 to 0.32 | 0.047 | 0.062 |
| CTBS | Di-N-acetylchitobiase | 0.13 | −0.05 to 0.31 | 0.147 | 0.184 |
| HP | Haptoglobin | 0.14 | −0.06 to 0.34 | 0.180 | 0.214 |
| FGG | Fibrinogen gamma chain | 0.06 | −0.06 to 0.18 | 0.327 | 0.371 |
| FBLN1 | Fibulin-1 | 0.05 | −0.06 to 0.17 | 0.351 | 0.381 |
| IGKV1D-13 | Ig kappa variable 1D-13 | 0.11 | −0.30 to 0.52 | 0.603 | 0.628 |
| KNG1 | Kininogen-1 | −0.006 | −0.08 to 0.07 | 0.874 | 0.873 |
Definition of abbreviations: CI = confidence interval; FDR = false discovery rate; PrePF = preclinical pulmonary fibrosis.
Proteins found to be significant in the analysis of subjects with idiopathic pulmonary fibrosis versus those without pulmonary fibrosis were examined in the plasma of subjects with PrePF versus those without pulmonary fibrosis. Analysis was controlled for age, sex, and family relatedness in a linear mixed-effects model; raw P values are listed as well as adjustment for multiple testing. Proteins with FDR < 0.05 are italicized.